DIAGOMICS has been acquired by ZytoMax, supported by healthcare specialist Archimed investment firm
The owner of DIAGOMICS has sold the company to ZytoMax GmbH.
Founded in 2009 by Gwénola Tanneau and based in Blagnac, France, DIAGOMICS is a specialized retailer of oncology reagents for in-vitro diagnosis for laboratories, hospitals, clinics and research centers in France, Belgium, Luxemburg, Switzerland, Spain, Tunisia and Morocco. With a highly qualified technical service, the highest level of quality control and an optimal quality-price ratio, DIAGOMICS is recognized as an independent reference in the value-added distribution of support reagents to in-vitro diagnosticians.
Structured in 2021 by Archimed, a global investment firm focused on the healthcare industries, ZytoMax brings together the expertise of three companies, ZytoMed, ZytoVision and 42Life Sciences. Based in Berlin, Germany, ZytoMax specializes in the development, manufacture and distribution of diagnostic reagents and system solutions for immunohistology, in-situ hybridization and molecular pathology. The company employs more than 110 people throughout Europe.
Oaklins’ team in France advised DIAGOMICS, a distributor of oncology reagents, on its affiliation with ZytoMax GmbH.
Gwénola Tanneau
Founder and CEO, DIAGOMICS
Talk to the deal team
Related deals
INNOTEX has been acquired by Clearspring Capital Partners
INNOTEX, a manufacturer of personal protective equipment for firefighters and first responders, has completed a strategic partnership with Clearspring Capital Partners.
Learn moreGARAIO has been acquired by Netrics Group
Netrics Group has acquired GARAIO AG as a wholly owned subsidiary. GARAIO will continue to operate as an independent company under the umbrella of Netrics Group. With this acquisition, Netrics Group is further expanding its leading position as a provider of managed cloud and digital workplace solutions as well as consulting services.
Learn moreAptic has received a minority investment from Sofiouest
The shareholders of Aptic have completed a primary minority LBO with Sofiouest.
Learn more